AndroMETa-CRC-064: An Open Label, Randomized, Controlled, Global Phase III Study Comparing ABBV-400 Monotherapy to LONSURF (Trifluridine and Tipiracil) plus Bevacizumab in Subjects with c-Met Over-Exp

Activity Type
Clinical Trial
Date
Dollar Amount
*
Grant Type
Contract
Principal Investigator
Aaron Scott
Sponsor
AbbVie Incorporated
Unit
Cancer Center Division